


- Listed in Hong Kong, Regent Pacific is primarily a healthcare and life science investment Group
- In 2014, the Group formally shifted its focus to the biopharma sector, where the vast majority of its investment is now focused today
- Its principal investments are Plethora Solutions, a UK pharmaceutical company specializing in urology, which the Group acquired 100% of in 2016, and Diabetic Boot Company, in which it owns a 22% stake
- Established in the Cayman Islands in 1991, the Group listed in Hong Kong on 19 May 1997

Financial Performance

Key highlights:




DEBT FREE with **US\$6.22m** in cash, listed & unlisted securities as at 30 Jun 2017

In the 20 years of financial reporting since IPO, Regent Pacific has returned approx. US\$298 million to shareholders:


Major recent investments and disposal highlights

- The acquisition of London listed Plethora Solutions through a recommended share exchange offer was completed in March 2016. Plethora Solutions became a wholly-owned subsidiary of the Group
- Additional investments into The Diabetic Boot Company Limited was completed, increasing Regent Pacific's stake to 22%
- Binary Limited was disposed of in April 2015 and June 2016 respectively for an aggregate consideration of US\$16.15 million, realising a "cash-on-cash" return of 13.02 times
- Condor Gold was disposed of in January 2017 for an aggregate consideration of approx. US\$2.51 million


Current key holdings include:



Carrying value of Group's major investments (comparing with total assets) as at 30 Jun 17 by sectors (USD)*



Carrying value of Group assets (comparing with total assets) as at 30 Jun 17 by investments (USD)*



Product Portfolio

Fortacin™



Highlights

- A brand under Plethora Solutions
- Fortacin™ is the first EU approved prescription treatment for premature ejaculation that doesn't act on the central nervous system, developed and owned by the Group
- Successfully launched in the UK in November 2016 through commercial partner Recordati; will further roll out in Europe in early 2018
- Under the partnership, the Group will receive important milestone and recurring royalty payments from Recordati on the commercialisation of Fortacin™
- Potential launch in Hong Kong and Macau in late 2018 upon granting of regulatory approval
- Approval from the US Food and Drug Administration is anticipated by Q4 2019, with commercial launch to follow shortly thereafter
- Discussions are ongoing with new potential commercial partners to out-license Fortacin™ in other key markets, including APAC, Middle East, Latin America, North America and Sub-Sahara Africa

PulseFlowDF™



Highlights

- A brand under The Diabetic Boot Company Limited
- PulseFlowDF™ is a product designed by The Diabetic Boot Company Limited to treat diabetes related foot ulcers
- Commercial manufacturing has already commenced in the UK with first sales taking place in August 2016 in the US
- Diabetic Boot has received Durable Medical Equipment, Prosthetics, Orthotics and Supplies accreditation in all 50 states and the District of Columbia
- During the period ended 30 June 2017, Diabetic Boot commenced commercialisation of PulseFlowDF directly in the US and through distributors in a number of other countries.
- The product has now proven to be reliable, well received by doctors and the clinical outcomes of the patients has been overwhelmingly positive.

Board Members

- James Mellon - Non-Executive Chairman
- Jamie Gibson - Executive Director and Chief Executive Officer
- David Comba - Independent Non-Executive Director
- Julie Oates - Independent Non-Executive Director
- Mark Searle - Independent Non-Executive Director
- Jayne Sutcliffe - Non-Executive Director

Senior Management Team

- Jamie Gibson - Executive Director and Chief Executive Officer
- Michael Wyllie - Chief Scientific Officer
- David Samuel Church - Head of Mergers and Acquisitions and General Counsel
- Paul Eric Jones - Investment Director

Profile of Jamie Gibson, Chief Executive Officer

- Joined Regent Pacific Group in April 1996 and was appointed as an Executive Director and Chief Operating Officer of the Group in January 2002
- Became CEO of the Group in May 2002
- Worked at Clifford Chance, Coopers & Lybrand and KPMG prior to joining the Group
- Spent most of his professional career with the Group specialising in corporate finance, direct equity investments and structuring emerging market investment products
- Appointed as CEO and Executive Director of Plethora Solutions in January 2014

Profile of Dr Michael Wyllie, Chief Scientific Officer

- Led the research and marketing team at Pfizer that developed Viagra and a co-founder of Plethora Solutions
- Possessed over 30 years of experience in senior management level positions within the pharmaceutical industry, with Wyeth and Pfizer
- Provides scientific overview and input to the development of Fortacin™, and responsible for securing approvals, regulatory compliance and commercialization of the product
- Works with Regent Pacific's senior management team to identify and evaluate exciting high growth and opportunistic 'late stage' investment opportunities in the life sciences sector